Skip to main content

Phase 2 and 3 studies

Edited by: 
Cristophe NicotKansas University Medical Center, USA

Submission Status: Open   |   Submission Deadline: 15th January 2024 


Molecular Cancer is calling for submissions to our Collection on 'Phase 2 and 3 studies.' Topics of interest include original reports on human clinical trials phase 2 and phase 3 as well as reviews of recently reported clinical trials.

About the collection

Molecular Cancer is calling for submissions to our Collection on 'Phase 2 and 3 studies.'

Topics of interest include original reports on human clinical trials phase 2 and phase 3 as well as reviews of recently reported clinical trials. The collection also invites authors to submit research article or correspondence related to clinical biomarkers of disease progression and/or resistance to commonly used therapies. The collection is open to submissions till 15th January 2024.

Image credit: © vitanovski / Stock.adobe.com

  1. Despite the effectiveness of the various targeted therapies currently approved for solid tumors, acquired resistance remains a persistent problem that limits the ultimate effectiveness of these treatments. Pol...

    Authors: Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, Mariella Spalato-Ceruso, Mihaela Aldea, Damien Vasseur, Melissa Alame, Laura Blouin, Isabelle Soubeyran, Claudio Nicotra, Maud Ngocamus, Antoine Hollebecque, Yohann Loriot, Benjamin Besse…
    Citation: Molecular Cancer 2023 22:176
  2. Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal compone...

    Authors: Hao Zhang, Xinghai Yue, Zhe Chen, Chao Liu, Wantao Wu, Nan Zhang, Zaoqu Liu, Liping Yang, Qing Jiang, Quan Cheng, Peng Luo and Guodong Liu
    Citation: Molecular Cancer 2023 22:159
  3. Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to...

    Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hernández-Jover, Antonio Gutierrez, Cesar Serrano…
    Citation: Molecular Cancer 2023 22:127
  4. Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free ...

    Authors: Lorraine Dalens, Julie Niogret, Corentin Richard, Sandy Chevrier, Pascal Foucher, Bruno Coudert, Aurélie Lagrange, Laure Favier, Virginie Westeel, Stefano Kim, Olivier Adotevi, Caroline Chapusot, Laurent Martin, Laurent Arnould, Courèche-Guillaume Kaderbhai and Romain Boidot
    Citation: Molecular Cancer 2023 22:120

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles, Reviews, and Correspondence. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Phase 2 and 3 studies" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editor has no competing interests with the submissions which are handled through the peer review process. The peer review of any submissions for which the Editor has competing interests is handled by another Editorial Board Member who has no competing interests.